Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tucidinostat + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone
- Development stage
- Phase 3
- Lead developer
- Akeso
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This drug is a six-drug combination therapy combining **tucidinostat**, a selective histone deacetylase (HDAC) inhibitor, with the R-CHOP chemotherapy regimen (**rituximab, cyclophosphamide, doxorubicin, vincristine,** and **prednisone**) for hematologic malignancies, especially diffuse large B-cell lymphoma (DLBCL) with MYC and BCL2 double expression. Tucidinostat impairs tumor cell proliferation and survival via epigenetic modulation; rituximab is a monoclonal antibody against CD20 on B cells; cyclophosphamide is an alkylating agent; doxorubicin is an anthracycline cytotoxic agent; vincristine is a microtubule inhibitor; prednisone is a glucocorticoid. The combination is intended to improve efficacy in highly aggressive lymphomas by leveraging multiple mechanisms: targeted immunotherapy, chemotherapy, and epigenetic modulation[1][2][3][4][5].
- Brand names
- Epidaza
- Other names
- chidamide plus R-CHOPchidamide combined with R-CHOP
02
Targets
CD20 (B-lymphocyte antigen CD20)DNATOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on tucidinostat + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tucidinostat + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone.